Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of aficamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
2021-003536-92Phase 3Completed
- Sponsor
- Cytokinetics
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing aficamten with placebo (2 arms). Primary endpoint: Change in peak oxygen uptake (pVO2). Started Feb 2022; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2021-003536-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003536-92.